About TearScience
TearScience is a company based in Morrisville (United States) founded in 2005 was acquired by Johnson & Johnson Vision in September 2017.. TearScience has raised $150.73 million across 5 funding rounds from investors including HealthCare Royalty Partners, De Novo Ventures and Spray Venture Partners. The company has 35 employees as of December 31, 2019. TearScience offers products and services including ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System. TearScience operates in a competitive market with competitors including Bruder Healthcare, Oculeve, Tear Film Innovations, Eyedetec Medical and Sinopsys Surgical, among others.
- Headquarter Morrisville, United States
- Employees 35 as on 31 Dec, 2019
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tearscience, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$150.73 M (USD)
in 5 rounds
-
Latest Funding Round
$19.23 M (USD), Series D
Apr 12, 2016
-
Investors
HealthCare Royalty Partners
& 7 more
-
Employee Count
35
as on Dec 31, 2019
-
Acquired by
Johnson & Johnson Vision
(Sep 08, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TearScience
TearScience offers a comprehensive portfolio of products and services, including ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides vision correction and eye health support for patients.
Offers tools to manage and prevent myopia progression.
Enables efficient ordering of products for eye care professionals.
Funding Insights of TearScience
TearScience has successfully raised a total of $150.73M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $19.23 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series D — $19.2M
-
First Round
First Round
(01 Jun 2005)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2016 | Amount | Series D - TearScience | Valuation |
investors |
|
| Feb, 2013 | Amount | Series D - TearScience | Valuation |
investors |
|
| May, 2010 | Amount | Series C - TearScience | Valuation | De Novo Ventures , Spray Venture Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TearScience
TearScience has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HealthCare Royalty Partners, De Novo Ventures and Spray Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TearScience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TearScience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tearscience Comparisons
Competitors of TearScience
TearScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bruder Healthcare, Oculeve, Tear Film Innovations, Eyedetec Medical and Sinopsys Surgical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Solutions for dry eye and pain management are developed.
|
|
| domain | founded_year | HQ Location |
A non-invasive nasal device for dry eye treatment is developed.
|
|
| domain | founded_year | HQ Location |
Evaporative dry eye is treated through meibomian gland stimulation devices.
|
|
| domain | founded_year | HQ Location |
Develops devices for the treatment of dry eyes
|
|
| domain | founded_year | HQ Location |
Offers lacrimal stents and procedures designed to effectively treat sinusitis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about TearScience
When was TearScience founded?
TearScience was founded in 2005.
Where is TearScience located?
TearScience is headquartered in Morrisville, United States.
Is TearScience a funded company?
TearScience is a funded company, having raised a total of $150.73M across 5 funding rounds to date. The company's 1st funding round was a Series C of $44.5M, raised on Jun 01, 2005.
How many employees does TearScience have?
As of Dec 31, 2019, the latest employee count at TearScience is 35.
What does TearScience do?
TearScience is a developer of devices that provide clinical identification and treatment of evaporative dry eye. Evaporative dry eye is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eyes natural tear film. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. The LipiFlow Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland while protecting the structures of the patients eye. TearSciences LipiFlow Thermal Pulsation System, Korb Meibomian Gland Evaluator, Lipi View products are FDA approved.
Who are the top competitors of TearScience?
TearScience's top competitors include Oculeve, Tear Film Innovations and Bruder Healthcare.
What products or services does TearScience offer?
TearScience offers ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System.
Who are TearScience's investors?
TearScience has 8 investors. Key investors include HealthCare Royalty Partners, De Novo Ventures, Spray Venture Partners, Investor Growth Capital, and unknown.